Revance Therapeutics (NASDAQ:RVNC): Negative Stock Sentiment

Sentiment for Revance Therapeutics (NASDAQ:RVNC)

Revance Therapeutics (NASDAQ:RVNC) institutional sentiment decreased to 1.31 in 2018 Q2. Its down -0.75, from 2.06 in 2018Q1. The ratio has worsened, as 55 institutional investors increased and started new holdings, while 42 sold and reduced their stakes in Revance Therapeutics. The institutional investors in our partner’s database now hold: 32.89 million shares, up from 32.18 million shares in 2018Q1. Also, the number of institutional investors holding Revance Therapeutics in their top 10 holdings was flat from 0 to 0 for the same number . Sold All: 18 Reduced: 24 Increased: 35 New Position: 20.

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company has market cap of $854.79 million. The company's lead drug candidate is DaxibotulinumtoxinA for injection , which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It currently has negative earnings. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development.

The stock decreased 4.50% or $1.09 during the last trading session, reaching $23.11. About 346,943 shares traded or 28.61% up from the average. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 7.74% since December 8, 2017 and is uptrending. It has underperformed by 7.88% the S&P500.

Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on February, 27. They expect $-0.97 earnings per share, up 14.91 % or $0.17 from last year’s $-1.14 per share. After $-0.91 actual earnings per share reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 6.59 % negative EPS growth.

Sio Capital Management Llc holds 1.54% of its portfolio in Revance Therapeutics, Inc. for 101,292 shares. Fosun International Ltd owns 472,532 shares or 0.66% of their US portfolio. Moreover, Rhenman & Partners Asset Management Ab has 0.57% invested in the company for 203,181 shares. The Colorado-based Arrowmark Colorado Holdings Llc has invested 0.45% in the stock. Essex Investment Management Co Llc, a Massachusetts-based fund reported 87,355 shares.

Since January 1, 0001, it had 0 insider purchases, and 3 selling transactions for $73,185 activity.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Ratings Coverage

Ratings analysis reveals 50% of Revance Therapeutics’s analysts are positive. Out of 2 Wall Street analysts rating Revance Therapeutics, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. RVNC was included in 2 notes of analysts from September 17, 2018. The rating was downgraded by JMP Securities on Monday, September 17 to “Market Perform”. The rating was upgraded by Guggenheim to “Buy” on Friday, November 16.

More notable recent Revance Therapeutics, Inc. (NASDAQ:RVNC) news were published by: Businesswire.com which released: “Revance Releases Second Quarter 2018 Results – Business Wire” on August 02, 2018, also Businesswire.com with their article: “Revance to Participate in Upcoming Investor Conferences – Business Wire” published on November 20, 2018, Seekingalpha.com published: “Revance Therapeutics: An Undervalued Botox Competitor – Seeking Alpha” on August 17, 2017. More interesting news about Revance Therapeutics, Inc. (NASDAQ:RVNC) were released by: Nasdaq.com and their article: “Health Care Sector Update for 12/04/2018: NVLN, RVNC, ARDS – Nasdaq” published on December 04, 2018 as well as Benzinga.com‘s news article titled: “Goldman Sachs Sees 100% Upside In This Biopharma Company (NASDAQ:RVNC) – Benzinga” with publication date: March 05, 2018.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.